| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1988PNAS...85.1932P |
| P356 | DOI | 10.1073/PNAS.85.6.1932 |
| P932 | PMC publication ID | 279895 |
| P698 | PubMed publication ID | 2450351 |
| P5875 | ResearchGate publication ID | 20706485 |
| P50 | author | Barton Haynes | Q4865631 |
| Kent J. Weinhold | Q109935303 | ||
| Dani Bolognesi | Q109936341 | ||
| T J Palker | Q125313333 | ||
| P2093 | author name string | T J Matthews | |
| A J Langlois | |||
| M E Clark | |||
| R R Randall | |||
| P2860 | cites work | Genomic heterogeneity of AIDS retroviral isolates from North America and Zaire. | Q53896192 |
| Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS) | Q22242256 | ||
| Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications | Q24561689 | ||
| Conformational parameters for amino acids in helical, beta-sheet, and random coil regions calculated from proteins | Q28240446 | ||
| Complete nucleotide sequence of the AIDS virus, HTLV-III | Q28259080 | ||
| The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus | Q28259668 | ||
| Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS | Q28262859 | ||
| Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor | Q28646793 | ||
| Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule | Q28646808 | ||
| Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1 | Q28646812 | ||
| T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV | Q28646817 | ||
| Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS | Q29614260 | ||
| Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. | Q30355613 | ||
| Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions. | Q30356755 | ||
| Induction of anti-HIV neutralizing antibodies by synthetic peptides | Q33880796 | ||
| Isolation of Lymphocytopathic Retroviruses from San Francisco Patients with AIDS | Q34250436 | ||
| A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope | Q34614992 | ||
| Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide | Q34632476 | ||
| Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins | Q35076867 | ||
| Hydrophobic basis of packing in globular proteins | Q36401816 | ||
| Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody | Q37399845 | ||
| Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein | Q37412527 | ||
| Variable and conserved neutralization antigens of human immunodeficiency virus | Q38891686 | ||
| Expression of the HTLV-III envelope gene by a recombinant vaccinia virus | Q39500655 | ||
| AIDS retrovirus induced cytopathology: giant cell formation and involvement of CD4 antigen | Q41830365 | ||
| Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity | Q43894349 | ||
| Use of a resin-bound synthetic peptide for identifying a neutralizing antigenic determinant associated with the human immunodeficiency virus envelope | Q44207603 | ||
| Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein | Q44509170 | ||
| Immunogenic structure of the influenza virus hemagglutinin | Q45805278 | ||
| Expression of AIDS virus envelope gene in recombinant vaccinia viruses | Q45837045 | ||
| Genomic diversity of human T-lymphotropic virus type III (HTLV-III). | Q45838359 | ||
| HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope | Q45848174 | ||
| Genetic variability of the AIDS virus: nucleotide sequence analysis of two isolates from African patients | Q45848343 | ||
| Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS. | Q48363856 | ||
| Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein. | Q53534022 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virus | Q808 |
| antibody | Q79460 | ||
| P1104 | number of pages | 5 | |
| P304 | page(s) | 1932-1936 | |
| P577 | publication date | 1988-03-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides | |
| P478 | volume | 85 |
| Q30886684 | 3D structure model of the principal neutralizing epitope of Minnesota HIV-1 isolate |
| Q37386161 | A HIV-1 heterosexual transmission chain in Guangzhou, China: a molecular epidemiological study |
| Q37634237 | A broadly neutralizing monoclonal antibody that recognizes the V3 region of human immunodeficiency virus type 1 glycoprotein gp120. |
| Q34306804 | A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 |
| Q35569049 | A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses |
| Q38315995 | A model of a gp120 V3 peptide in complex with an HIV-neutralizing antibody based on NMR and mutant cycle-derived constraints |
| Q36801560 | A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization |
| Q36821056 | A predominant group-specific neutralizing epitope of human immunodeficiency virus type 1 maps to residues 342 to 511 of the envelope glycoprotein gp120. |
| Q36686562 | A single amino acid substitution in hypervariable region 5 of the envelope protein of feline immunodeficiency virus allows escape from virus neutralization |
| Q34552313 | A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. |
| Q34610959 | Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4. |
| Q27489000 | Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates |
| Q36600380 | Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. |
| Q36633911 | Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization |
| Q36622298 | Amino acid substitutions in the human immunodeficiency virus type 1 gp120 V3 loop that change viral tropism also alter physical and functional properties of the virion envelope. |
| Q27485984 | An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. |
| Q33307183 | An evolutionary-network model reveals stratified interactions in the V3 loop of the HIV-1 envelope. |
| Q47970652 | An immunoassay with bovine serum albumin coupled peptides for the improved detection of anti V3 antibodies in HIV-1 positive human sera |
| Q33570776 | An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. |
| Q35848683 | An infectious chimeric human immunodeficiency virus type 2 (HIV-2) expressing the HIV-1 principal neutralizing determinant |
| Q40359188 | Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates |
| Q36782627 | Analysis of a highly immunodominant epitope in the human immunodeficiency virus type 1 transmembrane glycoprotein, gp41, defined by a human monoclonal antibody |
| Q36635246 | Analysis of a rape case by direct sequencing of the human immunodeficiency virus type 1 pol and gag genes |
| Q37603996 | Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody |
| Q34648429 | Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection |
| Q28752503 | Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes |
| Q36634341 | Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum |
| Q33571605 | Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120 |
| Q36641374 | Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans |
| Q52847698 | Antibody Responses of Chimpanzees Immunized with Synthetic Peptides Corresponding to Full-Length V3 Hypervariable Loops of HIV-1 Envelope Glycoproteins |
| Q64945136 | Antibody responses to a mucosally delivered HIV-1 gp120-derived C4/V3 peptide. |
| Q36811962 | Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees |
| Q27473441 | Antigenic structure of the hepatitis C virus envelope 2 protein |
| Q39879382 | Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. |
| Q36644253 | Autologous antibody response against the principal neutralizing domain of human immunodeficiency virus type 1 isolated from infected humans |
| Q36687749 | Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses |
| Q36695580 | Blocking of human immunodeficiency virus infection depends on cell density and viral stock age |
| Q36647416 | Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation |
| Q41706173 | Broadly Reactive Antibody-Dependent Cellular Cytotoxic Response to HIV-1 Envelope Glycoproteins Precedes Broad Neutralizing Response in Human Infection |
| Q67899864 | Cellular and humoral antigenic epitopes in HIV and SIV |
| Q39236502 | Change in tropism upon immune escape by human immunodeficiency virus |
| Q35127401 | Characterization of HIV-1 subtype C envelope glycoproteins from perinatally infected children with different courses of disease |
| Q71848107 | Characterization of a soluble, oligomeric HIV-1 gp160 protein as a potential immunogen |
| Q36649958 | Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding |
| Q33785114 | Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys |
| Q35607085 | Characterization of the cDNA of a broadly reactive neutralizing human anti-gp120 monoclonal antibody |
| Q45741970 | Chimeras between the human immunodeficiency virus (HIV-1) Env and vaccinia virus immunogenic proteins p14 and p39 generate in mice broadly reactive antibodies and specific activation of CD8+ T cell responses to Env. |
| Q35837816 | Chimeras from a human rhinovirus 14-human immunodeficiency virus type 1 (HIV-1) V3 loop seroprevalence library induce neutralizing responses against HIV-1. |
| Q37284795 | Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies |
| Q36654435 | Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1 |
| Q43993034 | Comparison and fine mapping of both high and low neutralizing monoclonal antibodies against the principal neutralization domain of HIV-1 |
| Q45859740 | Comparison of Linear Antigenic Sites in the Envelope Proteins of Human Immunodeficiency Virus (HIV) Type 2 and Type 1 |
| Q36126775 | Comparison of variable region 3 sequences of human immunodeficiency virus type 1 from infected children with the RNA and DNA sequences of the virus populations of their mothers |
| Q40062738 | Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody |
| Q31010762 | Conformational preferences of the HIV-1 principal neutralizing determinant |
| Q33809112 | Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. |
| Q38356824 | Contribution of arginine residues in the RP135 peptide derived from the V3 loop of gp120 to its interaction with the Fv fragment of the 0.5beta HIV-1 neutralizing antibody |
| Q36361373 | Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein |
| Q27736064 | Core structure of gp41 from the HIV envelope glycoprotein |
| Q36454330 | Covariation of mutations in the V3 loop of human immunodeficiency virus type 1 envelope protein: an information theoretic analysis |
| Q41663440 | Cross-Neutralizing Antibodies in Rabbits Immunized with HIV-1 gp160 Purified from Simian Cells Infected with a Recombinant Vaccinia Virus |
| Q36698091 | Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates |
| Q36634499 | Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. |
| Q33782574 | Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients |
| Q57499148 | Cross-reactive T-cell proliferative responses to V3 peptides corresponding to different geographical HIV-1 isolates in HIV-seropositive individuals |
| Q36648079 | Cross-reactive lysis of human targets infected with prototypic and clinical human immunodeficiency virus type 1 (HIV-1) strains by murine anti-HIV-1 IIIB env-specific cytotoxic T lymphocytes |
| Q27731780 | Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen |
| Q27639371 | Crystal structure of a human rhinovirus that displays part of the HIV-1 V3 loop and induces neutralizing antibodies against HIV-1 |
| Q67663083 | Defining minimal requirements for antibody production to peptide antigens |
| Q39577967 | Delayed infection after immunization with a peptide from the transmembrane glycoprotein of the feline immunodeficiency virus |
| Q38739398 | Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies |
| Q36690394 | Detailed mapping of the antigenicity of the surface unit glycoprotein of equine infectious anemia virus by using synthetic peptide strategies |
| Q33821658 | Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo |
| Q33898692 | Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees |
| Q39092457 | Different B-cell responses to human T-cell lymphotropic virus type I (HTLV-I) envelope synthetic peptides in HTLV-I-infected individuals |
| Q27646554 | Different Vaccine Vectors Delivering the Same Antigen Elicit CD8+ T Cell Responses with Distinct Clonotype and Epitope Specificity |
| Q36646318 | Dilute passage promotes expression of genetic and phenotypic variants of human immunodeficiency virus type 1 in cell culture. |
| Q33937274 | Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein |
| Q30714991 | Dual specificity of a human neutralizing monoclonal antibody, specific for the V3 loop of GP120 (HIV-1). |
| Q40043205 | Effect of a single amino acid substitution in the V3 domain of the human immunodeficiency virus type 1: generation of revertant viruses to overcome defects in infectivity in specific cell types |
| Q45784287 | Effect of anti-V3 antibodies on cell-free and cell-to-cell human immunodeficiency virus transmission |
| Q36872993 | Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1 |
| Q36812220 | Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. |
| Q45874261 | Enhanced proliferative cellular responses to HIV-1 V3 peptide and gp120 following immunization with V3:Ty virus-like particles |
| Q35833979 | Enhanced sensitivity to neutralizing antibodies in a variant of equine infectious anemia virus is linked to amino acid substitutions in the surface unit envelope glycoprotein |
| Q36230737 | Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41 |
| Q40393218 | Envelope Sequence Variation, Neutralizing Antibodies, and Primate Lentivirus Persistence |
| Q36811030 | Envelope cross-reactivity between human immunodeficiency virus types 1 and 2 detected by different serological methods: correlation between cross-neutralization and reactivity against the main neutralizing site. |
| Q64135308 | Enzyme immunoassay (ELISA) for the evaluation of antibodies directed to the CD4 receptor-binding site of the HIV gp120 molecule |
| Q33782296 | Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage |
| Q35887052 | Evolution of human immunodeficiency virus type 1 in perinatally infected infants with rapid and slow progression to disease |
| Q33927239 | Evolution of sequences encoding the principal neutralization epitope of human immunodeficiency virus 1 is host dependent, rapid, and continuous |
| Q39579497 | Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity |
| Q36698665 | Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine |
| Q50133392 | Expression and immunogenicity of V3 loop epitopes of HIV-1, isolates SC and WMJ2, inserted in Salmonella flagellin |
| Q38354263 | Expression, purification, and isotope labeling of the Fv of the human HIV-1 neutralizing antibody 447-52D for NMR studies |
| Q41119643 | FP-21399 blocks HIV envelope protein-mediated membrane fusion and concentrates in lymph nodes |
| Q33649657 | Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251. |
| Q42808224 | Functional and Immunological Characterization of SIV Envelope Glycoprotein Produced in Genetically Engineered Mammalian Cells |
| Q36650881 | Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions |
| Q36830136 | Functional interaction of constant and variable domains of human immunodeficiency virus type 1 gp120. |
| Q37788337 | GP4-specific neutralizing antibodies might be a driving force in PRRSV evolution |
| Q24806405 | Generating neutralizing antibodies, Th1 response and MHC non restricted immunogenicity of HIV-I env and gag peptides in liposomes and ISCOMs with in-built adjuvanticity |
| Q35832182 | Genetic analysis of human immunodeficiency virus type 1 envelope V3 region isolates from mothers and infants after perinatal transmission |
| Q52216971 | Global and local structural properties of the principal neutralizing determinant of the HIV-1 envelope protein gp120. |
| Q33671780 | Group-specific, major histocompatibility complex class I-restricted cytotoxic responses to human immunodeficiency virus 1 (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV-1-infected individual |
| Q35839936 | Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. |
| Q34242666 | HIV vaccine development at Duke University Medical Center. |
| Q43501040 | HIV-1 Neutralizing Antibody and Approaches to the Envelope Diversity Problem |
| Q55241966 | HIV-1 Neutralizing Monoclonal Antibodies Induced by a Synthetic Peptide |
| Q35113720 | HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation |
| Q27000480 | HIV-1 neutralizing antibodies: understanding nature's pathways |
| Q71803147 | HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques |
| Q36708990 | HIV-neutralizing antibodies: epitope identification and significance for future vaccine |
| Q37471315 | High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination |
| Q45227185 | Human MoAbs produced from normal, HIV-1-negative donors and specific for glycoprotein gp120 of the HIV-1 envelope |
| Q36690417 | Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity |
| Q33933855 | Human immunodeficiency virus type 1 major neutralizing determinant exposed on hepatitis B surface antigen particles is highly immunogenic in primates |
| Q36365085 | Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer |
| Q36780203 | Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping |
| Q37051645 | Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma |
| Q69117601 | Human monoclonal antibodies against a recombinant HIV envelope antigen produced by primary in vitro immunization. Characterization and epitope mapping |
| Q34145199 | Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. |
| Q33880904 | Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain |
| Q32157115 | Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1. |
| Q27486056 | Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus |
| Q35315868 | Humoral immune responses in human HIV-1 infection clearance of initial burst of virus replication and protection against disease progression |
| Q36647277 | Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion |
| Q37546827 | Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity |
| Q36690500 | Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120 |
| Q41736501 | Identification of Conserved and Variant Epitopes of Human Immunodeficiency Virus Type 1 (HIV-1) gp120 by Human Monoclonal Antibodies Produced by EBV-Transformed Cell Lines |
| Q40106499 | Identification of a uniquely immunodominant, cross-reacting site in the human immunodeficiency virus endonuclease protein |
| Q45854225 | Identification of amino acids in the V3 region of gp120 critical for virus neutralization by human HIV-1-specific antibodies |
| Q45747320 | Identification of human immunodeficiency virus type 1 subtypes B and F B/F recombinant and dual infection with these subtypes in Argentina |
| Q36781270 | Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins |
| Q40015450 | Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein. |
| Q36687883 | Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain |
| Q36655438 | Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: evidence for multiple pathways |
| Q37634281 | Immunizations of monkeys with synthetic peptides disclose conserved areas on gp120 of human immunodeficiency virus type 1 associated with cross-neutralizing antibodies and T-cell recognition |
| Q38705312 | Immunobiology of the HIV envelope |
| Q45858856 | Immunogenicity of Synthetic Peptides Corresponding to Various Epitopes of the Human Immunodeficiency Virus Envelope Protein |
| Q47855338 | Immunoglobulin G abnormalities in HIV-1 infected individuals with lymphoma |
| Q45056043 | Immunological reactivity of a human immunodeficiency virus type I derived peptide representing a consensus sequence of the GP120 major neutralizing region V3 |
| Q39550518 | Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV |
| Q36487349 | Impact of IgA constant domain on HIV-1 neutralizing function of monoclonal antibody F425A1g8. |
| Q36949880 | Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response |
| Q43661193 | In Vivo Sequence Variation of the Human Immunodeficiency Virus Type 1envGene: Evidence for Recombination Among Variants Found in a Single Individual |
| Q36558933 | In silico Analysis of HIV-1 Env-gp120 Reveals Structural Bases for Viral Adaptation in Growth-Restrictive Cells |
| Q36699146 | In vivo genetic variability of the human immunodeficiency virus type 2 V3 region |
| Q39603619 | Induction and characterization of neutralizing antibodies against a human immunodeficiency virus type 1 primary isolate |
| Q33794744 | Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains |
| Q37540957 | Induction of antibodies to the envelope protein of the human immunodeficiency virus by immunization with monoclonal anti-idiotypes |
| Q27486239 | Induction of cytotoxic T cells to a cross-reactive epitope in the hepatitis C virus nonstructural RNA polymerase-like protein |
| Q36688133 | Induction of high-titer neutralizing antibodies, using hybrid human immunodeficiency virus V3-Ty viruslike particles in a clinically relevant adjuvant |
| Q33724169 | Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1. |
| Q33933098 | Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160 |
| Q41581854 | Inhibition of human immunodeficiency virus infection by the lectin jacalin and by a derived peptide showing a sequence similarity with gp120. |
| Q28368050 | Inhibition of human immunodeficiency virus type 1 infection and syncytium formation in human cells by V3 loop synthetic peptides from gp120 |
| Q35848446 | Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies |
| Q39872343 | Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period |
| Q34280115 | Isolation of HIV-1-neutralizing mucosal monoclonal antibodies from human colostrum |
| Q36009232 | Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones |
| Q44025958 | Liposomal encapsulation enhances antiviral efficacy of SPC3 against human immunodeficiency virus type-1 infection in human lymphocytes. |
| Q39875204 | Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein |
| Q55242221 | Mapping of IgG subclass and T-cell epitopes on HIV proteins by synthetic peptides. |
| Q33785510 | Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. |
| Q36702147 | Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins |
| Q35781187 | Molecular analysis of TCR and peptide/MHC interaction using P18-I10-derived peptides with a single D-amino acid substitution |
| Q30778843 | Monoclonal Antibodies to the Extracellular Domain of HIV-1IIIB gp160 that Neutralize Infectivity, Block Binding to CD4, and React with Diverse Isolates |
| Q28369349 | Multibranched V3 peptides inhibit human immunodeficiency virus infection in human lymphocytes and macrophages |
| Q30420728 | Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1. |
| Q40308489 | Mutations in the principal neutralization determinant of human immunodeficiency virus type 1 affect syncytium formation, virus infectivity, growth kinetics, and neutralization |
| Q73402698 | NMR study of the peptide present in the principal neutralizing determinant (PND) of HIV-1 envelope glycoprotein gp120 |
| Q36655953 | Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons |
| Q39595739 | Naturally occurring mutations within 39 amino acids in the envelope glycoprotein of maedi-visna virus alter the neutralization phenotype |
| Q38332760 | Naturally occurring mutations within HIV-1 V3 genomic RNA lead to antigenic variation dependent on a single amino acid substitution |
| Q73520511 | Neutralization epitopes of the HIV-1 primary isolate DH012 |
| Q36699076 | Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1 |
| Q41172474 | Neutralizing antibodies and antigens in AIDS |
| Q36881981 | Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. |
| Q36366296 | Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation. |
| Q35839457 | Neutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120 |
| Q33639792 | Nuclear magnetic resonance analysis of solution conformations in C4-V3 hybrid peptides derived from human immunodeficiency virus (HIV) type 1 gp120: relation to specificity of peptide-induced anti-HIV neutralizing antibodies |
| Q45859829 | Patterns of antibody reactivity to selected human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in infected individuals grouped according to CD4+ cell levels |
| Q36708999 | Peptide component vaccine engineering: targeting the AIDS virus |
| Q93081608 | Peptide-Based Vaccination for Antibody Responses Against HIV |
| Q45859269 | Peptides Mimicking Selected Disulfide Loops in HIV-1 gp120, Other Than V3, Do Not Elicit Virus-Neutralizing Antibodies |
| Q36844406 | Peptides isolated from random peptide libraries on phage elicit a neutralizing anti-HIV-1 response: analysis of immunological mimicry |
| Q38014963 | Peptides: chemistry, biology, and pharmacology |
| Q36814860 | Permissive residues within the minimal epitopes of neutralizing monoclonal antibodies to the V3 loop of HIV-1. |
| Q40041200 | Persistence of simian immunodeficiency virus Mne variants upon transmission |
| Q27733366 | Perturbations in the surface structure of A22 Iraq foot-and-mouth disease virus accompanying coupled changes in host cell specificity and antigenicity |
| Q36697652 | Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule |
| Q35844007 | Phenotypic and genotypic characteristics of human immunodeficiency virus type 1 from patients with AIDS in northern Thailand |
| Q36697629 | Poliovirus chimeras expressing sequences from the principal neutralization domain of human immunodeficiency virus type 1 |
| Q37567048 | Prediction of optimal peptide mixtures to induce broadly neutralizing antibodies to human immunodeficiency virus type 1 |
| Q70807097 | Preventive and therapeutic AIDS peptide vaccines |
| Q37610962 | Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides |
| Q72092275 | Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles |
| Q34301897 | Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein |
| Q36384117 | Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors |
| Q41706764 | Production of Immunogenic HIV-1 Viruslike Particles in Stably Engineered Monkey Cell Lines |
| Q36699099 | Protection against Friend retrovirus-induced leukemia by recombinant vaccinia viruses expressing the gag gene. |
| Q62009584 | Pseudoproline: Induktion einer biologisch relevantencis-Peptidbindung in Mimetika der V3-Schleife des HIV-1-Proteins gp120 |
| Q27642457 | Recurring conformation of the human immunodeficiency virus type 1 gp120 V3 loop |
| Q35828735 | Relationship between the V3 loop and the phenotypes of human immunodeficiency virus type 1 (HIV-1) isolates from children perinatally infected with HIV-1. |
| Q40061779 | Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region |
| Q30416200 | Resistance of Subtype C HIV-1 Strains to Anti-V3 Loop Antibodies. |
| Q35873306 | Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites |
| Q36409768 | Role of HIV-1 subtype C envelope V3 to V5 regions in viral entry, coreceptor utilization and replication efficiency in primary T-lymphocytes and monocyte-derived macrophages |
| Q28368122 | SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms |
| Q39594428 | Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. |
| Q41547625 | Separation and partial characterization of proteinases with substrate specificity for basic amino acids from human MOLT-4 T lymphocytes: identification of those inhibited by variable-loop-V3 peptides of HIV-1 (human immunodeficiency virus-1) envelop |
| Q38890604 | Sequence Analysis of the V3 Loop Regions of theenvGenes of Ugandan Human Immunodeficiency Proviruses |
| Q34648342 | Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif. |
| Q36360966 | Sequential immunizations with rgp120s from independent isolates of human immunodeficiency virus type 1 induce the preferential expansion of broadly crossreactive B cells |
| Q41597581 | Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network |
| Q32157141 | Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque |
| Q62727136 | Simple strategy to induce antibodies of distinct specificity: Application to the mapping of gp120 and inhibition of HIV-1 infectivity |
| Q37186228 | Simple, sensitive, and specific detection of human immunodeficiency virus type 1 in clinical specimens by polymerase chain reaction with nested primers |
| Q37239053 | Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1 |
| Q37084521 | Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses |
| Q41667538 | Soluble CD4-PE40 Is Cytotoxic for a Transfected Mammalian Cell Line Stably Expressing the Envelope Protein of Human Immunodeficiency Virus (HIV-1), and Cytotoxicity Is Variably Inhibited by the Sera of HIV-1-Infected Patients |
| Q44244988 | Solution Structure of an Antibody-Bound HIV-1(IIIB) V3 Peptide: A Cis Proline Turn Linking Two β-hairpin Strands |
| Q45967960 | Solution conformation of an immunogenic peptide derived from the principal neutralizing determinant of the HIV-2 envelope glycoprotein gp125. |
| Q36884458 | Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies |
| Q36644697 | Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160 |
| Q27658173 | Structural Basis of the Cross-Reactivity of Genetically Related Human Anti-HIV-1 mAbs: Implications for Design of V3-Based Immunogens |
| Q31112947 | Structural analysis of the HIV-1 gp120 V3 loop: application to the HIV-Haiti isolates |
| Q44279032 | Structure and polymorphism of the principal neutralization site of Thailand HIV-1 isolate |
| Q35879339 | Study of the dynamics of neutralization escape mutants in a chimpanzee naturally infected with the simian immunodeficiency virus SIVcpz-ant |
| Q30238730 | Survivors Remorse: antibody-mediated protection against HIV-1. |
| Q28324011 | Synergistic combinations and peptides in the inhibition of human immunodeficiency virus |
| Q38665396 | Synthetic T and B cell recognition sites: implications for vaccine development |
| Q28369122 | Synthetic multimeric peptides derived from the principal neutralization domain (V3 loop) of human immunodeficiency virus type 1 (HIV-1) gp120 bind to galactosylceramide and block HIV-1 infection in a human CD4-negative mucosal epithelial cell line |
| Q40484822 | Synthetic peptides as diagnostic tools in virology. |
| Q57607867 | Synthetic peptides representing sequences within gp41 of HIV as immunogens for murine T- and B-cell responses |
| Q42550971 | Synthetic soluble analogs of galactosylceramide (GalCer) bind to the V3 domain of HIV-1 gp120 and inhibit HIV-1-induced fusion and entry |
| Q39189758 | The N-linked glycan of the V3 region of HIV-1 gp120 and CXCR4-dependent multiplication of a human immunodeficiency virus type 1 lymphocyte-tropic variant. |
| Q40433970 | The Role of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins in Virus Infection |
| Q38949380 | The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection |
| Q36055538 | The auto-regulation model: a unified concept of how HIV regulates its infectivity, pathogenesis and persistence |
| Q74248184 | The binding of a glycoprotein 120 V3 loop peptide to HIV-1 neutralizing antibodies. Structural implications |
| Q30769950 | The capsid gene of feline calicivirus contains linear B-cell epitopes in both variable and conserved regions |
| Q38366893 | The immunopathogenesis of HIV infection |
| Q37388157 | The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12. |
| Q36704527 | The molecular structure of human antibodies specific for the human immunodeficiency virus |
| Q36839199 | The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1 |
| Q40354016 | The quest for an antibody-based HIV vaccine |
| Q36809662 | The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope |
| Q36954472 | The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. |
| Q73935005 | Thermodynamic analysis of the interaction between the 0.5beta Fv fragment and the RP135 peptide antigen derived from the V3 loop of HIV-1 gp120 |
| Q44745703 | Towards covalent vaccination: improved polyclonal HIV neutralizing antibody response induced by an electrophilic gp120 V3 peptide analog |
| Q37924787 | Use of deuterium labelling in NMR studies of antibody combining site structure |
| Q41035907 | V3 Region Polymorphisms in HIV-1 from Brazil: Prevalence of Subtype B Strains Divergent from North American/European Prototype and Detection of Subtype F |
| Q40047131 | V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability. |
| Q34171212 | V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Tria |
| Q33839402 | Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope |
| Q34402934 | Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection |
| Q35848078 | Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. |
| Q39591825 | Variability and immunogenicity of caprine arthritis-encephalitis virus surface glycoprotein |
| Q30417537 | Variability of human immunodeficiency virus type 1 group O strains isolated from Cameroonian patients living in France |
| Q36632917 | Variability of the env gene in cynomolgus macaques persistently infected with human immunodeficiency virus type 2 strain ben. |
| Q36353458 | Variants selected by treatment of human immunodeficiency virus-infected cells with an immunotoxin |
| Q36829102 | Variation in simian immunodeficiency virus env is confined to V1 and V4 during progression to simian AIDS. |
| Q33564746 | Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain |
| Q45785271 | Vertical transmission of human immunodeficiency virus type 1: autologous neutralizing antibody, virus load, and virus phenotype |
Search more.